genmab
seattle
genetics
present
data
tisotumab
vedotin
innovatv
pivotal
trial
recurrent
metastatic
cervical
cancer
esmo
virtual
congress
media
release
copenhagen
denmark
bothell
september
data
featured
proffered
paper
oral
presentation
biologics
license
application
submission
planned
support
accelerated
approval
pathway
fda
genmab
nasdaq
gmab
seattle
genetics
nasdaq
sgen
today
presented
data
innovatv
pivotal
phase
clinical
trial
evaluating
tisotumab
vedotin
monotherapy
patients
previously
treated
recurrent
metastatic
cervical
cancer
european
society
medical
oncology
esmo
virtual
congress
patients
previously
received
doublet
chemotherapy
eligible
bevacizumab
therapy
results
trial
showed
percent
confirmed
objective
response
rate
orr
independent
central
review
median
duration
response
dor
months
common
adverse
events
greater
equal
percent
included
alopecia
epistaxis
nose
bleeds
nausea
conjunctivitis
fatigue
dry
eye
tisotumab
vedotin
investigational
conjugate
adc
directed
tissue
factor
tf
prevalent
solid
tumors
including
cervical
cancer
promote
tumor
growth
angiogenesis
current
therapies
previously
treated
recurrent
metastatic
cervical
cancer
generally
result
limited
objective
response
rates
typically
less
percent
median
overall
survival
ranging
following
resistance
progression
standard
care
therapy
limited
treatment
options
women
metastatic
cervical
cancer
said
robert
coleman
chief
scientific
officer
us
oncology
research
lead
investigator
innovatv
clinical
trial
current
treatment
approaches
disease
setting
low
objective
response
rates
poor
outcomes
results
tisotumab
vedotin
phase
clinical
trial
encouraging
demonstrate
clinically
meaningful
durable
responses
manageable
side
effect
encouraged
innovatv
trial
results
suggests
tisotumab
vedotin
monotherapy
could
potentially
become
important
option
women
metastatic
recurrent
cervical
cancer
said
jan
van
de
winkel
chief
executive
officer
genmab
seattle
genetics
genmab
committed
making
difference
lives
cancer
patients
look
forward
working
fda
goal
make
potential
treatment
option
available
women
quickly
tisotumab
vedotin
demonstrated
meaningful
clinical
activity
patients
recurrent
metastatic
cervical
cancer
high
unmet
need
new
therapies
said
roger
dansey
chief
medical
officer
seattle
genetics
based
results
look
forward
submitting
biologics
license
application
fda
accelerated
approval
data
presented
esmo
include
primary
endpoint
confirmed
orr
assessed
independent
central
review
patients
treated
tisotumab
vedotin
trial
secondary
endpoints
included
dor
time
response
survival
pfs
overall
survival
os
safety
tolerability
tisotumab
vedotin
previously
treated
recurrent
metastatic
cervical
cancer
results
phase
innovatv
study
abstract
proffered
paper
oral
presentation
cet
monday
september
efficacy
primary
endpoint
orr
complete
response
partial
response
showed
percent
confirmed
orr
confidence
interval
ci
including
patients
percent
complete
response
patients
percent
partial
response
median
months
median
dor
months
ci
reached
median
time
response
months
range
activity
generally
observed
within
first
two
treatment
cycles
subgroup
analyses
demonstrated
responses
generally
consistent
across
subgroups
regardless
tumor
histology
lines
prior
therapy
responses
prior
systemic
regimen
doublet
chemotherapy
bevacizumab
treatment
median
pfs
months
ci
pfs
rate
percent
ci
median
os
months
ci
os
rate
percent
ci
safety
common
adverse
events
greater
equal
percent
included
alopecia
grade
percent
epistaxis
nose
bleeds
grade
percent
nausea
grade
percent
conjunctivitis
grade
percent
fatigue
grade
percent
grade
higher
percent
dry
eye
grade
percent
adverse
events
grade
new
safety
signals
reported
one
death
due
septic
shock
considered
investigator
related
therapy
adverse
events
interest
tisotumab
vedotin
treatment
included
ocular
events
bleeding
peripheral
neuropathy
ocular
adverse
events
considered
related
therapy
occurred
patients
mostly
mild
moderate
grade
percent
grade
percent
grade
percent
majority
events
resolved
percent
managed
eye
care
plan
bleeding
events
considered
related
therapy
occurred
patients
mostly
mild
grade
percent
grade
percent
grade
percent
majority
events
resolved
percent
common
bleeding
events
included
grade
epistaxis
percent
peripheral
neuropathy
events
considered
related
therapy
mostly
mild
moderate
grade
percent
grade
percent
grade
percent
managed
dose
modifications
resolution
peripheral
neuropathy
limited
period
cervical
cancer
cervical
cancer
originates
cells
lining
cervix
women
expected
diagnosed
invasive
cervical
cancer
approximately
cervical
cancer
remains
one
leading
causes
cancer
death
women
globally
women
dying
annually
vast
majority
women
developing
routine
medical
examinations
human
papillomavirus
hpv
vaccines
lowered
incidence
cervical
cancer
developed
world
despite
advances
women
still
diagnosed
cervical
cancer
often
recurs
becomes
metastatic
innovatv
trial
innovatv
trial
also
known
innovatv
ongoing
global
multicenter
study
tisotumab
vedotin
patients
recurrent
metastatic
cervical
cancer
previously
treated
doublet
chemotherapy
without
bevacizumab
additionally
patients
eligible
received
two
prior
lines
therapy
recurrent
metastatic
setting
study
patients
treated
tisotumab
vedotin
multiple
centers
europe
primary
endpoint
trial
confirmed
objective
response
rate
per
response
evaluation
criteria
solid
tumors
recist
assessed
independent
central
review
key
secondary
endpoints
included
duration
response
survival
overall
survival
safety
tolerability
study
conducted
collaboration
european
network
gynaecological
oncological
trial
groups
engot
gynecologic
oncology
group
gog
information
phase
innovatv
clinical
trial
clinical
trials
tisotumab
vedotin
please
visit
tisotumab
vedotin
tisotumab
vedotin
investigational
conjugate
adc
composed
genmab
fully
human
monoclonal
antibody
specific
tissue
factor
seattle
genetics
adc
technology
utilizes
linker
covalently
attaches
agent
monomethyl
auristatin
e
mmae
antibody
releases
upon
internalization
inducing
target
cell
death
cancer
biology
tissue
factor
protein
promote
tumor
growth
angiogenesis
based
high
expression
many
solid
tumors
rapid
internalization
tissue
factor
selected
target
adc
approach
tisotumab
vedotin
genmab
seattle
genetics
agreement
companies
share
costs
profits
product
basis
tisotumab
vedotin
evaluated
ongoing
clinical
trials
monotherapy
range
solid
tumors
including
recurrent
metastatic
cervical
cancer
ovarian
cancer
solid
tumors
combination
commonly
used
therapies
recurrent
metastatic
cervical
cancer
trials
evaluating
tisotumab
vedotin
weekly
every
dosing
schedule
genmab
genmab
publicly
traded
international
biotechnology
company
specializing
creation
development
differentiated
antibody
therapeutics
treatment
cancer
founded
company
creator
following
approved
antibodies
daratumumab
agreement
janssen
biotech
treatment
certain
multiple
myeloma
indications
territories
including
europe
japan
subcutaneous
ofatumumab
agreement
novartis
ag
treatment
adults
relapsing
forms
multiple
sclerosis
teprotumumab
agreement
roche
granting
sublicense
horizon
therapeutics
plc
treatment
thyroid
eye
disease
subcutaneous
formulation
daratumumab
known
darzalex
daratumumab
approved
europe
treatment
adult
patients
certain
multiple
myeloma
indications
first
approved
genmab
created
therapy
ofatumumab
agreement
novartis
ag
approved
treatment
certain
chronic
lymphocytic
leukemia
indications
available
japan
also
available
territories
via
compassionate
use
oncology
access
programs
daratumumab
clinical
development
janssen
treatment
additional
multiple
myeloma
indications
blood
cancers
amyloidosis
genmab
also
broad
clinical
product
pipeline
genmab
technology
base
consists
validated
proprietary
next
generation
antibody
technologies
platform
generation
bispecific
antibodies
platform
creates
effector
function
enhanced
antibodies
platform
combines
two
acting
hexabody
molecules
introduce
selectivity
maximizing
therapeutic
potency
platform
enhances
potential
potency
bispecific
antibodies
hexamerization
company
intends
leverage
technologies
create
opportunities
full
future
products
genmab
alliances
top
tier
pharmaceutical
biotechnology
companies
genmab
headquartered
copenhagen
denmark
sites
utrecht
netherlands
princeton
new
jersey
tokyo
japan
seattle
genetics
seattle
genetics
global
biotechnology
company
discovers
develops
commercializes
transformative
cancer
medicines
make
meaningful
difference
people
lives
brentuximab
vedotin
enfortumab
use
company
conjugate
adc
technology
adcetris
approved
certain
lymphomas
padcev
approved
certain
metastatic
urothelial
cancers
tucatinib
small
molecule
tyrosine
kinase
inhibitor
approved
certain
metastatic
breast
cancers
company
headquartered
seattle
washington
area
locations
california
switzerland
european
union
information
robust
pipeline
visit
follow
seattlegenetics
twitter
contacts
genmab
media
marisol
peron
corporate
vice
president
communications
investor
relations
mmp
investors
andrew
carlsen
senior
director
investor
relations
acn
seattle
genetics
media
monique
greer
mgreer
investors
peggy
pinkston
ppinkston
genmab
forward
looking
statement
media
release
contains
forward
looking
statements
words
believe
expect
anticipate
intend
plan
similar
expressions
identify
forward
looking
statements
actual
results
performance
may
differ
materially
future
results
performance
expressed
implied
statements
important
factors
could
cause
actual
results
performance
differ
materially
include
among
others
risks
associated
clinical
development
products
uncertainties
related
outcome
conduct
clinical
trials
including
unforeseen
safety
issues
uncertainties
related
product
manufacturing
lack
market
acceptance
products
inability
manage
growth
competitive
environment
relation
business
area
markets
inability
attract
retain
suitably
qualified
personnel
unenforceability
lack
protection
patents
proprietary
rights
relationships
affiliated
entities
changes
developments
technology
may
render
products
technologies
obsolete
factors
discussion
risks
please
refer
risk
management
sections
genmab
recent
financial
reports
available
risk
factors
included
genmab
recent
annual
report
form
filings
securities
exchange
commission
sec
available
genmab
undertake
obligation
update
revise
forward
looking
statements
media
release
confirm
statements
reflect
subsequent
events
circumstances
date
made
relation
actual
results
unless
required
law
genmab
subsidiaries
following
trademarks
genmab
genmab
combination
genmab
duobody
combination
duobody
hexabody
combination
hexabody
trademarks
novartis
ag
affiliates
darzalex
trademarks
janssen
pharmaceutica
nv
trademark
horizon
therapeutics
plc
seattle
genetics
forward
looking
statement
certain
statements
made
press
release
forward
looking
among
others
relating
plans
submit
biologics
license
application
bla
fda
fda
accelerated
approval
program
based
results
innovatv
therapeutic
potential
tisotumab
vedotin
actual
results
developments
may
differ
materially
projected
implied
statements
factors
may
cause
difference
include
possibility
delays
submission
bla
fda
data
innovatv
may
sufficient
support
accelerated
approval
tisotumab
vedotin
difficulty
uncertainty
pharmaceutical
product
development
risk
adverse
events
safety
signals
inability
show
sufficient
activity
current
future
clinical
trials
possibility
adverse
regulatory
actions
information
risks
uncertainties
faced
seattle
genetics
contained
caption
risk
factors
included
company
quarterly
report
form
quarter
ended
june
filed
securities
exchange
commission
seattle
genetics
disclaims
intention
obligation
update
revise
statements
whether
result
new
information
future
events
otherwise
except
required
law
references
van
de
berg
yw
et
al
blood
miller
et
gynecol
oncol
bookman
et
gynecol
oncol
garcia
et
j
clin
oncol
monk
et
j
clin
oncol
santin
et
gynecol
oncol
schilder
et
gynecol
oncol
chung
hc
et
al
j
clin
oncol
national
cancer
institute
seer
cancer
stat
facts
cervix
uteri
available
https
statfacts
html
last
accessed
april
global
cancer
statistics
globocan
estimates
incidence
mortality
worldwide
cancers
countries
https
media
release
cvr
lei
code
genmab
kalvebod
brygge
copenhagen
v
denmark
attachment
